Incyte shares should be bought on weakness, says JMP Securities

Theflyonthewall.com – Thu, Aug 30, 2012 7:35 AM EDT

RELATED QUOTES

SymbolPriceChange
INCY20.36-1.05

After Incyte COO Pat Andrews left the company, JMP Securities doesn't anticipate that this development will have any long-term implications on the outlook for the company's myelofibrosis treatment, Jakafi. The firm reiterates an Outperform rating on the stock.

  •  
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
    Save List to Portfolio »

  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    How do you feel about the American Medical Association's decision to classify obesity as a disease?

    Loading...
    Poll Choice Options

    See results

    21 hours remaining